Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 147300
Corporate User License Price USD 6000
Corporate User License Price INR 441900
Site License Price USD 4000
Site License Price INR 294600
Request a Quote

Report Title

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline Review, H1 2017



Executive Summary

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline Review, H1 2017, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 3, 3, 1 and 1 respectively.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Overview

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Companies Involved in Therapeutics Development

AstraZeneca Plc

Bristol-Myers Squibb Company

Gilead Sciences Inc

Modus Therapeutics Holding AB

Novartis AG

NuvOx Pharma LLC

Pfizer Inc

Seattle Genetics Inc

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Drug Profiles

apixaban-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizanlizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVX-508-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

regadenoson-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivipansel sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sevuparin sodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGD-2083-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ticagrelor-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Dormant Projects

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Discontinued Products

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Product Development Milestones

Featured News & Press Releases

Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis

Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel

Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology

Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel

Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015

Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting

Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel

Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070)

May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial

Sep 13, 2013: GlycoMimetics Announces EMA's Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease

Aug 19, 2013: Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises

Jan 17, 2013: GlycoMimetics Completes Enrollment In Phase II Sickle Cell Disease Study With Lead Drug Candidate GMI-1070

Dec 11, 2012: Glycomimetics Presents Data From Pilot Study Of GMI-1070 At ASH Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by AstraZeneca Plc, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by Bristol-Myers Squibb Company, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by Gilead Sciences Inc, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by Modus Therapeutics Holding AB, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by Novartis AG, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by NuvOx Pharma LLC, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by Pfizer Inc, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Pipeline by Seattle Genetics Inc, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Dormant Projects, H1 2017

Vaso-Occlusive Crisis Associated With Sickle Cell Disease-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AstraZeneca Plc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Modus Therapeutics Holding AB, Novartis AG, NuvOx Pharma LLC, Pfizer Inc, Seattle Genetics Inc

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutic Products under Development, Key Players in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Therapeutics, Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Overview, Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline, Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand